Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yep, always happens, especially being that it's a Friday. With all the buying we've had in the last couple of weeks, I don't think it was all just small retail, someone or some institution was buying, so I hope if the share price goes down to "X" point below $4, assuming "they" are still interested in buying more, they will start buying again when we reach "X". I have no idea what their X would be. I do know what my X is.
Good Luck to all
It's FRIDAY. Let's close out the week holding above $4.
Interesting and funny video that I give absolutely No Credence to, nor do I have any faith in the presenter ... as his statement that he already "made a lot of his subscribers rich since May 31st" with his MRKR recommendation and his understand of what MRKR does is "they have some sort of medication that kills cancer and tumors" is humorous. But in any case ....
A current $4.34 and a day high of $4.40. I wish I knew how much was Real Buy and Hold accumulation and how much are the short term traders riding the wave who will shortly ditch back out. I hope it's less of the latter. We will find out in a couple/few/several days the next time things settle out. But for right now, (for the old timers), as Tony the Tiger would say, GRRREAT.
Yep, the Knoxdaily "article" started with "Piper Sandler initiated its Marker Therapeutics Inc. [MRKR] rating to an Overweight in a research note published on Friday, March 25, 2021" and the last line of the paragraph I quoted was "However, 1 analyst have rated MRKR stock as a Buy in their predictions for 2023."
I just left them out because it didn't fit into the "dream" narrative.
Hopefully in time we can get more analysts on board, but I fear that won't happen until we present some impressive data.
Thanks for the 2 articles, interesting reading. From the Knoxdaily article, I liked this part:
"According to FactSet, Marker Therapeutics Inc.’s share price will average $40.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 1512.9 percent from its previous closing price of $2.48. Analysts expect Marker Therapeutics Inc. stock to reach the higher price of $40.00, while the lowest price estimate is $40.00."
I'll be happy with that dream. It won't get me to the 28 Billion Jim Simons has made with his hedge fund, but I will get a teeny tiny bit closer. Ha Ha
As we were both Long Island based, I have communicated with Jim Simons from Renaissance Technologies in the past, strangely enough, about politics and education, not investing, but the man and the algorithms Renaissance use always have a knack for being ahead of the curve, so it would not surprise me to find out that he has jumped in and increased his MRKR holdings substantially, but that is nothing more than a meaningless conjecture right now. I would also LOVE to see NEA and Aisling increase their positions to lower their average cost. The more shares the Big Whales buy the lower the float, so when good news leads to retail wanting to buy a lot, the higher the price they will have to pay for the smaller amount of shares available .............. Just realized it is past midnight, so I may just be dreaming, but one can dream. ............ One more comment, if MRKR tech proves to actually work impressively, then note to Marker,
DO NOT ACCEPT A CRAZY CHEAP BUY OUT FROM ANY BIG PHARMA. Either do partnerships for new drug indications or MAKE THEM PAY BIG TIME FOR A BUY OUT. I know, getting WAY AHEAD of myself ....... still just dreaming.
August should be very interesting for a few reasons. #1, We will have gotten the strategic review from Juan Vera. #2, Because Institutional Holdings information reports are filed within 45 days after calendar quarter end with the vast majority of updates occurring near the 45th day of the quarter, we will KNOW who has been buying all the way through the end of June. #3, We may find out if any insiders have been buying recently at these current higher levels. Last time most insiders bought was at a pre split $1.75 ($17.50 post split), so even if they did, it would still be a lot cheaper than they bought in at last time. That would also be encouraging to see.
I know. Under the Peter Hoang regime I had sent several emails to various parties over the years.
Not a single person from either the company or their investor relations firms ever answered.
I find it very refreshing that we now (finally) have a company and a CEO that actually gives a (you know what) about their investors.
When I first heard the "in a few weeks" on May 24, my mind said ... one means one week .... a couple means 2 weeks ... a few means 3 or 4 weeks ... and several would mean 5 or more weeks. So when I heard "a few weeks" on May 24, I took it literally and expected the announcement by about mid June.
It appears that Juan meant several as opposed to a few, but I can live with it. At least it looks like both Juan and the company are trying to do much better in and for the future.
He just set the (new) date ... late July/early August. I believe that is what it will be.
This is actually the first time in a very long time that I feel good about this company (still down well over 6 figures). As I said on another MRKR message board ......
THANK GOD JUAN VERA REPLACED PETER HOANG.
By the way, Phantoms post # 33764 on June 5 WAS 100% CORRECT. I should have listened but I was too nervous and also too (in effect) greedy as I wanted to wait until a decent pull back, which now, WE MAY NOT GET AT ALL. But it's OK, I have owned a ton for many years now.
What the new information from Juan Vera concerning the "strategic review and restructuring of our clinical programs" now coming in late July/early August means .... that I was right about the June 12 MT-601 news was not the "strategic review" ..... BUT I WAS WRONG AS I SPECULATED THAT THE RECENT RUNUP IN STOCK PRICE WAS DUE TO INSIDERS KNOWING THAT THE strategic review NEWS WAS COMING VERY SOON (post # 33815 , June 16) .
What that means to me is that this current runup in stock price IS VERY GOOD NEWS (besides the price going up) because it is REAL and should hold and is NOT based on news that is coming soon that insiders knew about in advance.
Wish I bought a lot more on 3-23-23 at $1.11, but as I said, hindsight is 20/20.
Phantom, Don't know if you have been following, but the "strategic review and restructuring of our clinical programs" that was alluded to in the May 24 Proactive video coming "in a few weeks" is supposed to now happen "in late July/early August" from what Juan Vera just told me. Comments? Thank You
WOW got an answer from Juan Vera:
Dear Dennis,
Thank you for your question and your ongoing interest in our company.
The press release issued on June 12 on the first lymphoma patient treated with MT-601 in the company sponsored Phase 1 clinical trial was indeed an important milestone for us, and we understand the excitement and curiosity it has sparked among our shareholders.
While it’s an important part, it's not the entirety of the strategic restructuring of our clinical programs that we alluded to in the video interview with Proactive in May. This particular announcement, which promises a comprehensive view of the restructuring of our clinical program, is still forthcoming.
The strategic review and restructuring of our clinical programs is a comprehensive process. It's not about one single program or research direction, but rather a holistic reconsideration of how our clinical programs are developed and carried out. This review is designed to increase efficiency, foster innovation, and improve results across all areas of our work. We are currently in the final stages of preparing this comprehensive review and plan to present it in late July/early August.
We understand our shareholders’ eagerness to learn more about our strategic developments and the future direction of Marker Therapeutics. Please be assured that we are working diligently to provide clear, comprehensive and timely information, and we are looking forward to sharing more about our exciting new directions in the coming weeks.We remain committed to our mission of improving patient care through innovative immunotherapies, and we greatly appreciate your continued support and patience.
Best regards,
Juan
Message was:
Hello Mr. Vera, I am a very long time stock holder going back to early Tapimmune.
Was the June 12 announcement about MT-601/Lymphoma the "strategic
review and restructuring of the clinical programs" announcement that
you said would be coming in a few weeks in the May 24 Proactive video?
or should be still be expecting that overall big picture review?
Thank You,
I just sent an email to Juan Vera. If I get an answer I will let the board know what they contained.
I am waiting to hear the cogent answers to your questions that you posted.
In the first quarter of 2023, MILLENNIUM MANAGEMENT added about 14,000 shares to their position for a "then" total of about 31,000 shares bringing their total $ investment to 76 thousand, which is less than some retail holders.
Won't know until about August 15 what they (or anybody else) did in the second quarter 2023.
Todays upward move is the kind of move I like (with a qualifier discussed later).
Todays move, IF for NO apparent reason (no press release or trial data news) seems more substainable and holdable.
When you have a move based on a press release or trial data news, the SAME pattern seems to happen like clockwork.
Tick #1, retail jumps in. - price goes up (Monday).
Tick #2, daytraders jump in - price goes up more to unrealistic higher levels (Monday).
Ticks #'s 3, 4 + 5, Daytraders jump out and short sellers jump in and some retail take quick profit, all driving the price lower (Tuesday morning).
Tick #6, Stock price goes too low (Tuesday morning).
Tick #7, Short sellers buy to cover their short positions and some retail buy at the lower price, both giving the price a small uptick (Tuesday rest of day).
Tick #8, Stock with no external influences seeks new level (Wednesday + Thursday).
So today, Friday, we have a good upward move, which brings me back to the qualifier I started with.
IF, next week we get the "strategic review and restructuring of their clinical programs" that Juan Vera promised, then todays move I will chalk up to ... inside information causing the informed to buy ... and IF so, then the clockwork pattern will repeat.
By the way, what caused the quick runup prior to Mondays MT-601 news release ... YEP IMO, inside information causing the informed to buy.
I expect that very soon we may get the "strategic review and restructuring of their clinical programs" that Juan Vera promised, as I don't think Mondays MT-601 news WAS the "strategic review" of the overall Big Picture news Juan Vera inferred was coming "in the next few weeks", (at least I hope not and that there is more detailed info is coming).
WE SHALL SEE.
and now, as always, the day traders leave and the price will settle back to it's next new level.
Yes, but the point was ... it is NOT as you said "Still the Same Faces". The point was that "the only differerence" as you said was Not just a connection to Allovir.
Thank You Again for the info.
We still got a long way to go, but it beats the hell out of us pushing down to the $1 level and below once again as we were doing back in April.
Yes, you are absolutely correct once again. "Still the same people with no new faces except for the CMO."
With the CEO Peter Hoang gone and a new CFO, can an intelligent person actually say "Still the SAME people"?
Does that mean when somebody like PH disappears and Anthony Kim comes in as the new CFO, it is "STILL the SAME people"?
"The only difference is a stronger link to AlloVir through CEO Vera and a Director who now owns the manufacturing end of the process."
Would an intelligent person REALLY say that with new cash from the CellReady deal and a new trial started and dosed and a management shakeup that the ONLY DIFFERENCE is "a stronger link to AlloVir", which is meaningless?
Would an intelligent person REALLY say that "the ONLY DIFFERENCE is a stronger link to AlloVir" is the reason that the stock price has gone from $1.25 to $3.25 in the last month, getting close to tripling?
Yes, you keep on beating the same old tired dead horses if it makes you feel better about yourself.
I think an intelligent person WOULD say that foolish statements come from foolish people.
Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial.
https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-announces-first-lymphoma-patient-treated-mt
The first patient in the APOLLO trial recently received MT-601 at the 200 million cell dose level. This patient was monitored for 18 days after being dosed and showed no treatment-related adverse events, indicating that the therapy was well tolerated.
Under the APOLLO trial, eight clinical sites across the United States will cumulatively enroll up to 30 patients during the dose escalation phase.
I was buying MRKR $5 and $7.50 call options back in 2020 and early 2021, not alot in, about 3K, lost about 2K. A laughable joke compared to stock losses. Oh well, maybe in 3 years I'll break even on everything. One can only hope and in reality, it was just some of the profits from bio's like Pharmacyclics (bought by Abbvie), Cubist (bought by Merck), Alnylam, etc., etc. so really can't complain much in the big picture.
Yeah, the last time I bought was on 3-23-23 at $1.11, wish I bought ALOT more than I did but as the saying goes ...hindsight is 20/20.
Good Luck.
Well, being one of those legacy retail, I believe break even would be more in the $15 to $35 range.
I'm closer to the lower end of that range but that's only because I kept buying more and more as it went down and down.
If AML success (because it will be the first news), definately double digits easy, so price X.
If Lymphoma success, price X times 3 or 4 I would think.
If Pancreatic success (because by then MRKR would have a few more cancer trials going), I think most likely triple digits or triple digits with big pharma parter firms dumping in money or just a big pharma buyout for a ton of money.
I'd love to still be around to see it.
Exactly Correct
Hope soars high ... hopefully not on the wings of Icarus.
Just to play devils advocate ... Yep sounds good ... Pre Clinical in a Test Tube, but how many hundreds of other experiments seemed to work Pre Clinical in a Test Tube and then went nowhere, or worked in mice and then went nowhere, or seemed to work in phase 1 and then went nowhere.
Like LC, I also remember Peregrine (my second biggest loser after MRKR). I don't think I will be adding more shares on this rubberband stretching news.
We have about 9 million shares outstanding and about 33 million shares Traded so far, up to $1.95 and then the drift down started and buyers at $1.80, $1.85, $1.90, $1.95 are currently losing $. Most of those Traders could care less about the news, they are just playing momentum.
If I poured battery acid in a test tube and killed lymphoma cells, they would probably be playing that momentum also.
Buy on the rumor, Sell on the news. The news I would like to hear about is AML Adjuvant.
But I guess todays news is better than "we did X pre clinical in a test tube and it sucked."
"We need a public quarterly cc with Q&A."
What YOU need and what the laws require are two different things. Public companies like MRKR are not required to appease small change or no change investors just because they constantly cry, throw tantrums, or ask irrelevant questions.
"I remain concerned with the IP."
Congratulations, you seem to be the ONLY ONE who is.
"ALVR patents are worth exploring to compare."
Maybe, on the ALVR board.
"I like opinions. Thought that's what this board was for??"
Yes, this board is for opinions about MRKR.
"I just can't seem to grow up and comprehend what EVERYBODY has tried to explain to me at least a dozen times"
BINGO
What possible answer could there be for relevance to the MRKR board.
They both do biotech?, they both are from America?, they both are based on planet Earth?, all of the employees of both breath oxygen? ... in other words, NOTHING.
The real question is .... when the facts are presented and understood in the proper context,
will any lesson be learned before future commentary .... I highly doubt it.
Geez, I ran out of the "patience" part a Long Time Ago. Happy Memorial Day.
As long as I am rambling on, I'll go on. I've been investing in stocks since the 1980's.
I have always thought of an individual stock price as a rubberband.
That rubberband is almost NEVER non stretched and at it's "fair" price (although conventional market wisdom says stocks always find their natural level). That rubberband is almost ALWAYS stretched either too high or too low because of all the varied market influences on it.
Day traders stretch it too high, Short sellers stretch it too low, options buyers and sellers can stretch it either way, greed stretches it too high, fear stretches it too low, good news or a good earnings report breeds enthusiasm and optimism and greed, and the opposite breeds doubt and pessimism and fear.
Discord and other like sites and memes and talking heads on TV all stretch that rubberband one way or the other.
My point is, don't buy when it has a "reason" to be artificially stretched high, and vice versa.
The same rubberband theory also effects and applies to P/E ratios and P/E/G ratios.
It's all in the eye of the beholder.
GO MRKR.
Juan Vera said that in the NEXT FEW WEEKS an update is coming.
Before I go any further, look at what happened when the Cellready news came out.
It's what almost Always happens. The stock price shot up a bit, then the day traders jump in and out and in and out (which is why you got the large volume for a couple of days), and they drive the price up even more to an artificially high price (over $1.60 post Cellready news), and they they take their gained (and lost for some) money and leave, and then the price drifts back down to settle at it's next "real" (non day trader influenced) price.
So when Juan Vera does his thing in the NEXT FEW WEEKS (his words), the same thing will most likely happen again.
I think, if you want to "trade" or even hold more, either buy before the news or within a few minutes of it.
If you buy well after the news, just like with the Cellready news, you may wind up watching your high buy in price drift back down somewhat.
Good Luck to Juan and Marker and patients and investors.
Thank You Proactive for giving MRKR an extra 71 million dollars. It's 19 not 90, and we paid these dumbasses good money for (as Phantom pointed out) will be viewed by almost no one.
I feel like I'm in the Twilight Zone ... you ... me .... and LC ... all agree on something.
That proves that miracles can happen ... maybe one will happen with MRKR.
They did their deal, they got their money, they got about a year and a half to impress enough for real money to start flowing in based on something other than just hope.